Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma.
Yano Y, Yamamoto A, Mimura T, Kushida S, Hirohata S, Yoon S, Hirano H, Kim SK, Hatazawa Y, Momose K, Hayashi H, Kado T, Nishi K, Tanaka H, Matsuura T, Yoshida R, Asaji N, Yasutomi E, Shiomi Y, Minami A, Komatsu S, Fukumoto T, Ueda Y, Kodama Y.
Yano Y, et al. Among authors: yasutomi e.
JGH Open. 2023 Jun 15;7(7):476-481. doi: 10.1002/jgh3.12932. eCollection 2023 Jul.
JGH Open. 2023.
PMID: 37496817
Free PMC article.